It is a 'safe vaccine': SA kids taking part in Sinovac Covid-19 trials get their first jabs

accreditation
0:00
play article
Subscribers can listen to this article
  • Sinovac launched Covid-19 clinical trials for children aged from 6-months to 17 years old on Friday.
  • Two South African teenagers aged 17 were the first to receive their doses.
  • Participants will receive two doses of the vaccines, or a placebo, 28 days apart.

The first South African children who are part of Sinovac Covid-19 vaccine trials received their first jabs at the Sefako Makgatho University in GaRankuwa on Friday.

A 17-year-old boy and girl were the first to receive their dose. Their identities are being kept secret to protect their privacy.

Sinovac, through Numolox, which has the local licence for the vaccine, is conducting the first paediatric phase three Covid-19 trials in the country.

Sinovac’s medical director for clinical research, Gang Zeng, said the vaccine has already been administered to about 40 million children aged between three and 17 in China.

READ | Covid-19 vaccine: Sinovac to start South African trials on children

The South African Medical Research Council's (SAMRC) Professor Glenda Gray said this was the first step in getting a Covid-19 vaccine for children.

The trials will enrol 14 000 children in five countries to investigate the efficacy of the Covid-19 vaccine. Locally, 2 000 children will be enrolled in seven sites.

Safety data

These are the first steps of getting a vaccine for children in South Africa.

Dr Sanet Aspinall, principal coordinator for the trials, said: 

Sinovac is a safe vaccine. It has been tested and there’s been no safety issues for the vulnerable population.

The trials will be conducted at sites in Brits in the North West, Germiston, Newtown, Sandton and Sefako Makgatho University in Gauteng, as well as in Bellville and Paarl in the Western Cape.

Aspinall said as they were working with a vulnerable group, they would be giving the SA Health Products Regulatory Authority (Sahpra) safety data every two weeks.

The team is also starting the trials with the 12 to 17 age group, before moving to younger children.

Participants will receive two doses of the vaccines or a placebo 28 days apart. Efficacy assessments will include surveillance for Covid-19-like symptoms and laboratory confirmation of infections. An interim analysis will be done when 47 cases of the virus are reported.


If you come across Covid-19 vaccination information that you do not trust, read Covid-19 vaccine myths debunked: Get the facts here. If you can't find the facts you're looking for, email us at the address mentioned in the article and we will verify the information with medical professionals.

We live in a world where facts and fiction get blurred
In times of uncertainty you need journalism you can trust. For only R75 per month, you have access to a world of in-depth analyses, investigative journalism, top opinions and a range of features. Journalism strengthens democracy. Invest in the future today.
Subscribe to News24
Lockdown For
DAYS
HRS
MINS
Voting Booth
Should Proteas star Quinton de Kock continue playing at the T20 World Cup even if he doesn't take the knee in support of the fight against racism?
Please select an option Oops! Something went wrong, please try again later.
Results
Yes! He should be allowed to show his support any way he chooses
35% - 322 votes
No! If De Kock refuses to unite with his teammates, then he should be on the next plane home
12% - 106 votes
The only ones at fault here are Cricket SA, who have sabotaged another Proteas World Cup
53% - 482 votes
Vote
Rand - Dollar
14.97
-0.9%
Rand - Pound
20.59
-0.7%
Rand - Euro
17.37
-0.9%
Rand - Aus dollar
11.23
-0.8%
Rand - Yen
0.13
-1.3%
Gold
1,786.37
-0.4%
Silver
23.92
-0.9%
Palladium
1,983.25
-1.3%
Platinum
1,017.75
-1.4%
Brent Crude
86.40
+0.5%
Top 40
60,797
-0.3%
All Share
67,494
-0.2%
Resource 10
63,048
-0.9%
Industrial 25
87,148
+0.0%
Financial 15
14,043
+0.1%
All JSE data delayed by at least 15 minutes Iress logo
Editorial feedback and complaints

Contact the public editor with feedback for our journalists, complaints, queries or suggestions about articles on News24.

LEARN MORE